Reglan Tardive Dyskinesia Settlement: Claim Valuation Factors Overview

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

What factors affect the value of a Reglan tardive dyskinesia claim

Claim valuation considers severity of tardive dyskinesia, duration of Reglan use, strength of evidence linking the drug to the condition, and impact on daily life. Legal procedure involves filing within the statute of limitations. Consult a qualified attorney for personalized assessment.

From General Health Education to Occupational Exposure

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatment options. Within this broad context, discussions around medication side effects have historically emphasized patient education and informed consent. As the focus narrows from general health awareness to specific pharmaceutical exposures, a critical transition occurs when considering long-term or high-dose use of certain prescription drugs. In the domain of mass production, where consistency and efficiency are paramount, the occupational exposure concern shifts from the patient to the manufacturing environment. Workers involved in the production, packaging, or quality control of pharmaceutical compounds may face repeated contact with active ingredients, including those associated with neurological risks. This pivot from a general health framework to an occupational exposure perspective requires careful consideration of how cumulative contact in a production setting differs from therapeutic use. The transition thus moves from broad educational content about medication risks to a targeted evaluation of workplace safety protocols and exposure monitoring. This shift underscores the need for specialized risk assessment factors that account for industrial hygiene practices, duration of exposure, and individual susceptibility within the manufacturing workforce.

Bridging to Reglan-Associated Tardive Dyskinesia

Building on the occupational exposure framework, we now examine a specific pharmaceutical agent—Reglan (metoclopramide)—and its well-documented association with tardive dyskinesia (TD), a potentially irreversible movement disorder. The risk of developing TD increases with longer treatment duration and higher cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the prescribing information recommends using the drug for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For symptomatic gastroesophageal reflux, the maximum treatment duration is 12 weeks; for diabetic gastroparesis, treatment beyond 12 weeks should be avoided unless unavoidable, in which case routine monitoring for TD signs and symptoms is advised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Clinical presentation of TD includes involuntary, often disfiguring movements of the face or tongue, and sometimes the trunk or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The condition can be suppressed or masked by metoclopramide itself, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Mechanistically, metoclopramide acts as a dopamine receptor antagonist in the central nervous system, which is the pathway believed to underlie TD development. This pharmacological action is similar to that of antipsychotic drugs known to cause TD.

Epidemiological Evidence and Risk Factors

Epidemiological data on TD incidence with metoclopramide vary. A real-world study using the MarketScan Research database (2011-2020) analyzed TD rates in adults with at least 12 months of medical and pharmacy benefits, comparing metoclopramide-treated gastroparesis patients, untreated patients, and the general population (https://pubmed.ncbi.nlm.nih.gov/41588797/). This study aimed to reassess incidence estimates, which have ranged from 1% to 15% in older studies (https://pubmed.ncbi.nlm.nih.gov/41588797/). Another review of literature, including PubMed and Google Scholar searches, reported that the risk of TD from metoclopramide is low, approximately 0.1% per 1000 patient-years, which is far below the 1%-10% risk suggested in some treatment guidelines (https://pubmed.ncbi.nlm.nih.gov/31050085/). High-risk groups identified include elderly females, diabetics, patients with liver or kidney failure, and those on concomitant antipsychotic drug therapy, which lowers the threshold for neurological complications (https://pubmed.ncbi.nlm.nih.gov/31050085/).

Claim Valuation Factors for Reglan-Associated TD

From a settlement perspective, claim valuation factors for Reglan-associated TD include the adequacy of warnings provided to patients and prescribers. The FDA-mandated boxed warning clearly states that metoclopramide can cause TD, that risk increases with duration and cumulative dose, and that the drug should be used for the shortest time possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, historical prescribing practices may have involved longer-term use beyond recommended limits, particularly for conditions like gastroparesis where treatment options are limited (https://pubmed.ncbi.nlm.nih.gov/41588797/). The timeline between exposure and documented harm is critical: TD can develop after months or years of metoclopramide use, and symptoms may persist or become permanent even after drug discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who developed TD after prolonged Reglan use may have claims based on inadequate warning or failure to monitor for early signs. Settlement considerations also involve the severity and reversibility of TD, the patient's age and comorbidities, and the duration of Reglan exposure. The risk of TD is dose-dependent, and cumulative exposure is a key factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients with identifiable risk factors, such as diabetes or concurrent antipsychotic use, may have higher claim values due to increased susceptibility (https://pubmed.ncbi.nlm.nih.gov/31050085/). Additionally, the adequacy of medical monitoring and documentation of TD symptoms over time influences settlement outcomes. The FDA label advises immediate discontinuation of Reglan if TD signs or symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397), and failure to do so may strengthen a claim.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the primary risk factor for developing tardive dyskinesia from Reglan?

The primary risk factor is longer treatment duration and higher cumulative dosage of metoclopramide. The FDA boxed warning emphasizes using Reglan for the shortest duration necessary (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

How is claim value determined in Reglan-associated TD cases?

Claim valuation depends on warning adequacy, exposure duration, patient risk factors (e.g., diabetes, elderly, concurrent antipsychotic use), severity and reversibility of TD, and the timeline of harm. Adequate documentation and failure to monitor or discontinue Reglan upon symptom onset also influence settlement outcomes (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397) (https://pubmed.ncbi.nlm.nih.gov/31050085/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.